plexiform neurofibroma NF1
Rare disease · 2022–2024
2decisions
1medicine
2carried consumer input
51individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| selumetinib Treatment of symptomatic, inoperable plexiform neurofibroma(s) in paediatric patients aged 2 years and over with neurofibromatosis type 1 (NF1). | Mar 2024 | Recommended with restriction | 22 individuals Tumour Foundation |
| selumetinib Treatment of symptomatic, inoperable plexiform neurofibroma(s) in paediatric patients with neurofibromatosis type 1 (NF1) aged 2 to 18 years. | Nov 2022 | Not recommended | 29 individuals Tumour Foundation |
Who spoke
Tumour Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.